This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chiming Wei Articles by McLaughlin, J. S Search for Related Content PubMed PubMed Citation Articles by Chiming Wei, Articles by McLaughlin, J. S Social Bookmarking                         What's this?

The effect of angiotensin II on mitogen-activated protein kinase in human cardiomyocytes

Cardiovascular Molecular Research, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA, cwei@smail. umaryland.edu

Marcelo G Cardarelli

Cardiovascular Molecular Research, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Stephen W Downing

Cardiovascular Molecular Research, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA

Joseph S McLaughlin

Cardiovascular Molecular Research, Division of Cardiac Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA

The role of angiotensin II (Ang II)-receptors on mitogen-activated protein kinase (MAPK) activation in cardiomyocytes remains controversial. Therefore, the current study was designed to investigate the actions of AT₁- and AT₂-receptors on Ang II-induced extracellular signal-regulated kinase (ERK), p38 and the c-Jun N-terminal kinase (JNK) MAPK activities in human cardiomyocytes. Human cardiac tissue was obtained from open-heart surgery (n=6). The cardiac tissue was minced and incubated in the special tissue culture system for 24 hours in the absence or presence of Ang II (10^-7 M). These studies were repeated with the AT₁-receptor antagonist losartan (10^-6 M) or the AT₂-receptor antagonist PD-123319 (10^-6 M). Immunohistochemical staining and Western blot analysis with phospho-antibodies were performed to determine ERK, JNK and p38 activities. Ang II increased ERK and p38 activities in human cardiomyocytes. The effects of Ang II were abolished by losartan and enhanced by PD-123319. Co-incubation with both losartan and PD-123319 resulted in a decrease of ERK and p38 activities in cardiomyocytes. The immunohistochemical staining of JNK showed no significant differences between Ang II alone, Ang II plus losartan and Ang II plus PD-123319 groups. In conclusion, Ang II has a potent effect on ERK and p38 MAPK activities in cardiomyocytes, by acting through AT₁-receptors. This effect of Ang II is modified by AT₂-receptors. Therefore, Ang II, via AT₁- and AT₂-receptor stimulation, has a distinct effect on MAPK activity in cardiomyocytes.

Key Words: angiotensin II • AT1- and AT2-receptors • MAPK • ERK • p38 • JNK

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 4, 379-384 (2000)
DOI: 10.3317/jraas.2000.070


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. S. Ramalho, I. Alfany-Fernandez, A. Casillas-Ramirez, M. Massip-Salcedo, A. Serafin, A. Rimola, V. Arroyo, J. Rodes, J. Rosello-Catafau, and C. Peralta Are Angiotensin II Receptor Antagonists Useful Strategies in Steatotic and Nonsteatotic Livers in Conditions of Partial Hepatectomy under Ischemia-Reperfusion? J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 130 - 140. [Abstract] [Full Text] [PDF]